Neratinib, Fulvestrant, Trastuzumab Combo Aids Metastatic Breast Cancer
TUESDAY, Nov. 28, 2023 -- For patients with hormone receptor (HR)-positive HER2-mutant metastatic breast cancer (MBC) with progression on cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy, neratinib + fulvestrant + trastuzumab (N + F + T) is...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Herceptin | HIV AIDS | Hormones | Pharmaceuticals